e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cel-Sci Corporation Common Stock
(NY:
CVM
)
9.990
-0.110 (-1.09%)
Streaming Delayed Price
Updated: 11:07 AM EDT, Oct 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cel-Sci Corporation Common Stock
< Previous
1
2
3
4
Next >
CEL-SCI Announces Closing of $10 Million Public Offering
August 29, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $10 Million Public Offering
August 27, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering
August 27, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
August 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
August 13, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
July 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
July 11, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
July 11, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of Public Offering
May 23, 2025
From
CEL-SCI Corporation
Via
Business Wire
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
June 18, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of Public Offering
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Combination of Common Stock
May 19, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
May 15, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
April 23, 2025
From
CEL-SCI Corporation
Via
Business Wire
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
April 08, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
March 24, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $2.5 Million Offering
March 18, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $2.5 Million Offering
March 17, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
March 17, 2025
From
CEL-SCI Corporation
Via
Business Wire
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
March 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
February 20, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
February 18, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
January 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5 Million Offering
December 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5 Million Public Offering
December 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering of Common Stock
December 27, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
December 12, 2024
From
CEL-SCI Corporation
Via
Business Wire
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
November 07, 2024
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube